Lakefront Biotherapeutics (GLPGF) Depreciation & Amortization (CF) (2016 - 2020)

Lakefront Biotherapeutics (GLPGF) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $5.3 million the latest figure, recorded in Q2 2020.

• On a quarterly basis, Depreciation & Amortization (CF) rose 63.17% year-over-year to $5.3 million in Q2 2020; TTM through Jun 2026 was $0.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $63.1 million, up 28.19% from the prior year.
• Depreciation & Amortization (CF) was $5.3 million for Q2 2020 at Lakefront Biotherapeutics, up from $4.6 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.0 billion in Q2 2017 and troughed at -$2.1 billion in Q3 2017.
• A 5-year average of -$5.6 million and a median of $3.0 million in 2018 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 211301.51% in 2017 and sank 99.85% in 2018, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $3.6 million in 2016, then slumped by 71.44% to $1.0 million in 2017, then tumbled by 70.47% to $302470.1 in 2018, then jumped by 1221.44% to $4.0 million in 2019, then soared by 32.8% to $5.3 million in 2020.
• The last three Depreciation & Amortization (CF) figures came in at $5.3 million (Q2 2020), $4.6 million (Q1 2020), and $4.0 million (Q4 2019), per Business Quant data.